October 25, 2016 9:46 PM ET

Healthcare Equipment and Supplies

Company Overview of Fresenius USA, Inc.

Company Overview

Fresenius USA, Inc. manufactures and distributes equipment and disposable products for the treatment of kidney failure by hemodialysis and by peritoneal dialysis. Fresenius USA, Inc. was formerly known as Delmed, Inc. and changed its name to Fresenius USA, Inc. in December 1991. The company was founded in 1982 and is based in Walnut Creek, California. Fresenius USA, Inc. operates as a subsidiary of Fresenius Medical Care AG & Co. KGAA.

2637 Shadelands Drive

Walnut Creek, CA 94598

United States

Founded in 1982

1,600 Employees





Key Executives for Fresenius USA, Inc.

Corporate Group Vice President of Regulatory Affairs
Age: 67
Compensation as of Fiscal Year 2016.

Fresenius USA, Inc. Key Developments

U.S. Judicial Panel on Multidistrict Litigation Issues Order Regarding Fresenius GranuFlo/Naturalyte Dialysate Products Liability Litigation

U.S. Judicial Panel on multidistrict litigation issues order regarding Fresenius GranuFlo/NaturaLyte Dialysate products liability litigation. Defendants are Fresenius Medical Care Holdings, Inc. d/b/a Fresenius 1 Medical Care North America; Fresenius USA, Inc.; Fresenius USA Manufacturing, Inc.; and Fresenius USA Marketing, Inc. (collectively Fresenius) oppose the motion. In her motion to vacate, plaintiff principally argues that transfer should not take place unless and until her motion for remand to state court is decided. The company have held that a motion for remand alone generally is an insufficient basis to vacate a conditional transfer order. Indeed, it has 2 rejected similar arguments in support of motions to vacate conditional transfer orders in this litigation. Transfer Order at 1-2, In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig., MDL No. 2428 (J.P.M.L. Feb. 5, 2015), ECF No. 1023. Plaintiff can present her motion for remand to the transferee judge. See, e.g., In re Ivy, 901 F.2d 7, 9 (2d Cir. 1990); In re Prudential Ins. Co. of Am. Sales Practices Litig., 170 F. Supp. 2d 1346, 1347-48 (J.P.M.L. 2001). Plaintiff also contends that transfer to the District of Massachusetts will be inconvenient because she and many of the witnesses to decedent's dialysis treatment are located in Oklahoma. The Panel has held repeatedly that, while it might inconvenience some parties, transfer of a particular action often is necessary to further the expeditious resolution of the litigation taken as a whole. The transferee judge is in the best position to structure proceedings so as to minimize inconvenience to any individual party. After considering the argument of counsel, find that Jerry involves common questions of fact with the actions previously transferred to MDL No. 2428, and that transfer under 28 U.S.C. Section 1407 will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. In order centralizing this litigation, held that the District of Massachusetts was an appropriate Section 1407 forum for actions sharing factual questions arising out of allegations that plaintiffs suffered injury or death caused by the use of GranuFlo or NaturaLyte during hemodialysis, which allegedly may cause metabolic alkalosis in patients resulting in low blood pressure, hypokalemia, hypoxemia, hypercapnia, cardiac arrhythmia, or cardiopulmonary arrest. See In re Fresenius GranuFlo/NaturaLyte Dialysate Prods. Liab. Litig., 935 F. Supp. 2d 1362 (J.P.M.L. 2013). Jerry involves similar allegations that plaintiff's decedent suffered metabolic alkalosis, cardiac arrhythmia, and death as a result of the use of GranuFlo and/or NaturaLyte during hemodialysis. This action likewise involves factual questions relating to whether these products were defectively designed or manufactured, whether Fresenius, the manufacturer of these dialysate products, knew or should have known of the alleged propensity of these products to cause injury, and whether it provided adequate instructions and warnings with these products.

Fish & Richardson Wins Wrongful Termination and Breach of Contract Suit for Fresenius

The law firm of Fish & Richardson has successfully defended its long-term client, Fresenius USA, in a suit filed by Fresenius' former president of research and development, Moshsen Reihanifam. On January 30, a jury ruled for Fresenius in Reihanifam v. Fresenius Medical Care North America, et al., denying Reihanifam the $29 million he sought in damages. Reihanifam's claims included discrimination, harassment, retaliation, wrongful termination and breach of contract. Fresenius argued that all of the claims were baseless. The jury returned the verdict for Fresenius in less than two hours of deliberations.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Fresenius USA, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.